To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
235
Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
Treatment-emergent Adverse Events (TEAEs)
Number of patients with treatment emergent AEs
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CNS Network
Garden Grove, California, United States
Behavioral Research Specialists
Glendale, California, United States
Irvine Clinical Research
Irvine, California, United States
Synergy San Diego
Lemon Grove, California, United States
Pacific Research Partners, LLC
Oakland, California, United States
NRC Research Institute
Orange, California, United States
MCB Clinical Research centers, LLC
Colorado Springs, Colorado, United States
Clinical Neuroscience Solutions ( CNS Healthcare)-Jacksonville
Jacksonville, Florida, United States
Meridien Research
Maitland, Florida, United States
Florida Research Center, Inc.
Miami, Florida, United States
...and 61 more locations